Menopause Treatment In Dubai

Perimenopause is the transition leading up to menopause. During this time, ovarian hormone levels fluctuate and menstrual cycles may become shorter, longer, heavier, lighter or less predictable. Hot flushes, night sweats, disturbed sleep, mood changes, vaginal dryness and other symptoms can begin even while periods continue. Menopause is confirmed retrospectively after 12 consecutive months without a menstrual period, provided the absence of bleeding is not caused by hormonal contraception, pregnancy, medication or another condition. Postmenopause refers to the years after that point. The transition often lasts several years, but its timing and symptom pattern vary widely. Treatment can be considered during perimenopause when symptoms are troublesome; a patient does not need to wait until periods have stopped completely.

In otherwise healthy patients aged 45 or over, perimenopause and menopause are usually identified from symptoms and menstrual history without routine hormone blood tests. Hormone levels can fluctuate substantially during the transition, so a single result may be misleading. An FSH blood test may be considered when symptoms and cycle changes occur between ages 40 and 45, or when menopause is suspected before age 40. Diagnosis can be more complicated after hysterectomy or while using hormonal contraception, and testing may be needed when another condition—such as pregnancy, thyroid disease, anaemia or a bleeding disorder—is possible. The clinician should select investigations according to the history rather than ordering extensive hormone, tumour-marker or specialised functional panels for every patient.

Symptoms vary in type, severity and duration. Common concerns include hot flushes, night sweats, disrupted sleep, fatigue, headaches, palpitations, joint or muscle discomfort, low mood, anxiety, irritability, reduced concentration or “brain fog,” and changes in sexual desire. Lower oestrogen levels can also contribute to genitourinary syndrome of menopause, which may cause vaginal dryness, burning, irritation, painful sex, urinary urgency or recurrent urinary infections. Some symptoms have other possible causes, so they should not automatically be attributed to menopause. New chest pain, severe depression, neurological symptoms, heavy or unusual bleeding, or symptoms that substantially impair daily life require medical assessment. A personalised review helps identify which concerns are menopause-related and which need separate investigation.

Systemic menopausal hormone therapy—also called HRT or MHT—is the most effective treatment for bothersome hot flushes and night sweats and can also improve related sleep disruption. It may be supplied as a tablet, patch, gel or spray, with the formulation chosen according to symptoms, health history and preference. Patients with a uterus generally need a progestogen with systemic oestrogen to protect the womb lining; after hysterectomy, oestrogen alone is often used. For many healthy symptomatic patients younger than 60 or within 10 years of menopause onset, benefits often outweigh risks, but treatment must be individualised. Non-hormonal prescription options and menopause-specific cognitive behavioural therapy may be appropriate when hormones are unsuitable or not preferred.

HRT is safe and effective for many appropriately selected patients, but its benefits and risks depend on age, time since menopause, symptoms, formulation, dose and personal medical history. Systemic HRT may not be suitable—or may require specialist advice—for people with unexplained vaginal bleeding, certain hormone-sensitive cancers, previous blood clots, stroke, heart attack, significant cardiovascular disease or active liver disease. Oral and transdermal products do not have identical risk profiles; for example, a patch or gel may be preferred when clot risk is a concern. A uterus usually requires endometrial protection with a progestogen when systemic oestrogen is prescribed. HRT should be reviewed periodically, and any new bleeding, breast change, severe headache, chest pain, breathlessness or leg swelling should be reported promptly.

Evidence-based non-hormonal options are available for patients who cannot use HRT or prefer not to. Depending on symptoms and medical history, these may include menopause-specific cognitive behavioural therapy and prescription medicines such as selected SSRIs or SNRIs, gabapentin, or a neurokinin-receptor antagonist where licensed and clinically appropriate. Each option has potential side effects and interactions, so treatment should be prescribed after reviewing other medicines and relevant conditions. Regular exercise, a cool sleeping environment, limiting personal hot-flush triggers, stopping smoking and moderating alcohol support general health and may help some symptoms, although lifestyle measures alone may not control severe vasomotor symptoms. Herbal or compounded products are not automatically safer; evidence, purity and dosing can vary, and some interact with medicines or are unsuitable after hormone-sensitive cancer.

These symptoms may be part of genitourinary syndrome of menopause and often persist without treatment. Vaginal moisturisers used regularly and lubricants used during sexual activity are useful non-hormonal first steps. If symptoms continue, low-dose vaginal oestrogen supplied as a cream, tablet, pessary or ring can improve dryness, irritation and painful sex, with much lower systemic absorption than standard systemic HRT. Other prescription options may be considered when appropriate and available. Recurrent urinary symptoms still require assessment because infection, pelvic-floor dysfunction, skin conditions and other disorders can produce similar complaints. Anyone with a history of breast cancer or taking endocrine therapy should discuss local hormonal treatment with their menopause and oncology teams. Postmenopausal bleeding should never be assumed to come from dryness without evaluation.

Declining oestrogen accelerates bone loss around the menopause transition and can increase the later risk of osteoporosis and fractures. Midlife is also an important time to assess cardiovascular risk factors such as blood pressure, cholesterol, diabetes, smoking, activity and weight. Helpful measures include weight-bearing and resistance exercise, adequate dietary calcium and vitamin D, sufficient protein, avoiding smoking and limiting alcohol. Bone-density scanning is recommended according to age and individual fracture risk rather than automatically for every newly menopausal patient. Systemic HRT prevents bone loss while it is being used and may be appropriate for symptom control or selected bone-health indications, but it should not be started solely to prevent cardiovascular disease. Prevention plans should be tailored to medical history and baseline risk.

Any vaginal bleeding after 12 consecutive months without a period should be assessed promptly, even if it happens only once or is limited to spotting. Common causes include vaginal or endometrial thinning, polyps and HRT-related bleeding, but endometrial hyperplasia or cancer must be excluded. Unscheduled bleeding can occur during the first months after starting or changing HRT, yet it should still be reported—especially if it is heavy, persistent, recurrent, begins after a period of no bleeding, or continues beyond the timeframe advised by the treating clinician. Assessment may include examination, transvaginal ultrasound and, when indicated, endometrial sampling or hysteroscopy. Bleeding accompanied by severe pain, dizziness, fainting or substantial blood loss requires urgent medical care.

The cost of menopause treatment in Dubai depends on the consultation, whether clinically indicated tests are required, the chosen treatment and the frequency of follow-up. A personalised plan may involve lifestyle guidance, prescription HRT or non-hormonal medication, local vaginal therapy, screening or referral for bone and cardiovascular health, or evaluation of abnormal bleeding. In otherwise healthy patients aged 45 or over with typical symptoms, menopause is often diagnosed clinically, so extensive hormone testing is not routinely necessary. Ask whether the quotation includes the initial assessment, indicated blood tests or imaging, medication, prescription renewal and follow-up review. Insurance coverage varies by policy, diagnosis and treatment. EV Clinic can provide an individual quotation after reviewing symptoms, medical history and treatment goals.